PNAS: Autoimmunity against MDA5 induces fibrotic ILD in mice. In this murine model of dermatomyositis, treatment with either anti-CD4 or anti-IL-6 receptor antibody ameliorated the MDA5-induced fibrotic ILD. https://t.co/CahyGfTn4g https://t.co/lfpdgEvGmx

ICYMI: Sex Disparities in PsA/SpA https://t.co/55zwjR8mNR https://t.co/fhhekNpHVA

ILD Onset in MDA-5 Dermatomyositis MDA5 antibody-positive DM is a rare, aggressive and progressive subtype of DM. Its' severity is dependent on the development of progressive ILD, manifesting as either RPILD and CILD. https://t.co/08wAYj06DH https://t.co/TQWHGR27O9

World Congress on OP, OA & MSK Disorders Bone and musculoskeletal disease researchers and physicians from around the world will meet today in London for the opening of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. https://t.co/kzvWD4Rmki https://t.co/PJQREsJO9v

Neuropsychiatric SLE - 2/3 Improved at 12 Months The management and outcomes of neuropsychiatric systemic lupus erythematosus (NPSLE) can be challenging as there is limited data. https://t.co/p0GEtkUTdt https://t.co/EZhjH6PxWQ

TNFi mAbs, JAKi, –IL-17 are protective against Anterior Uveitis (AU) in AxSpA. Metanalysis of 44 RCTs shows AU IR: - TNF mAbs: 4.1 - etanercept 5.4 - IL-17i: 2.8 - JAKi: 1.5 - placebo: 10.8 https://t.co/sxqCXkD0up https://t.co/XWXUPmCtZr

Of 375 #Gout pts D/C pegloticase after a median of 8 infusions (taken 112days (max 1,240d). Only 73% had SUA < 6 during pegloticase. After D/C 84% went on ULT (63% allopurinol; 34% febuxostat; after mean 92d); after ≥ 30 days), 51% achieved SUA < 6 https://t.co/unkvt1whrs https://t.co/DgVpBgKXcm

Mental health in 1150 adolescents & young adults w/ juvenile idiopathic arthritis (age 15.6 yrs; Dz duration 7.2 yrs, 43% oligo-, 26% polyarthritis): 30% reported suicidal thoughts, 19% mod-severe depressive/anxious Sxs (moreso in Females OR 2.33) https://t.co/THW1IMqZpa https://t.co/IU2Kr3efYj

ICYMI: Top 5 Clinical Pearls in RA Management https://t.co/zWRXzHTtIo https://t.co/rbitB9oWQG

Canadian OBRI study in 692 RA pts shows pts treated w/ triple DMARD (MSH) stayed on Rx longer (15 mos) compared to MTX+LEF (9.6 mos); not significant but MTX/SSZ/HCQ had signif lower DAS28 @ 6 mos (3.4 vs 3.9) & at 12 mos (3.2 vs 3.5, p=0.0005) https://t.co/ieHeXvgj3n https://t.co/MEMA1nrUpy

Join us 4/16 for Tuesday Night Rheumatology at 6:30pm ET. This week we'll be focusing on Vasculitis Mavens with: Vasculitis & Pregnancy - Catherine Sims, MD GPA Management in 2024 - Anisha Dua, MD, MPH Treat to Target in Vasculitis - Philip Seo, MD https://t.co/6IaCdCodGf https://t.co/HlZ8OiZWc4

JAMA: SLE Review Drs.Siegel & Sammaritano (from HSS in NYC) published an impressive overview of SLE) in JAMA. This timely, well-written review covers the many complexities of this multi-organ disorder that affects nearly 3.4 million people worldwide. https://t.co/byr1hRA6rV https://t.co/wZeIdfTlH0